Sarepta Therapeutics

Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
Xconomy
Roche
Sarepta Therapeutics
FDA
Duchenne Muscular Dystrophy
SRP-9001
Flag link:
Pharma's gene and cell therapy ambitions will kick into high gear in 2020—despite some major hurdles
Pharma's gene and cell therapy ambitions will kick into high gear in 2020—despite some major hurdles
Fierce Pharma
gene therapy
reimbursement
drug manufacturing
Bristol-Myers Squibb
Pfizer
Biomarin
Sarepta Therapeutics
Gilead Sciences
CAR-T
Flag link:
In stunning twist, FDA approves Sarepta's Duchenne drug it rejected
In stunning twist, FDA approves Sarepta's Duchenne drug it rejected
Biopharma Dive
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Vyondys 53
Flag link:
Wave faces key test in bid to challenge Sarepta in DMD
Wave faces key test in bid to challenge Sarepta in DMD
Biopharma Dive
Wave Life Sciences
Sarepta Therapeutics
Exondys 51
Duchenne Muscular Dystrophy
Flag link:
Sarepta pays StrideBio $48M for preclinical gene therapies
Sarepta pays StrideBio $48M for preclinical gene therapies
Fierce Biotech
Sarepta Therapeutics
StrideBio
gene therapies
CNS
Flag link:
Why Sarepta Therapeutics' Q3 Was Better Than Expected
Why Sarepta Therapeutics' Q3 Was Better Than Expected
Motley Fool
Sarepta Therapeutics
earnings
Flag link:
Sarepta Therapeutics CEO playing nice with FDA over rejection of Duchenne drug
Sarepta Therapeutics CEO playing nice with FDA over rejection of Duchenne drug
Stat
Sarepta Therapeutics
Doug Ingram
FDA
Vyondys 53
Duchenne Muscular Dystrophy
Flag link:
Sarepta, in shadow of FDA setback, marks gene therapy progress
Sarepta, in shadow of FDA setback, marks gene therapy progress
BioPharma Dive
Sarepta Therapeutics
SRP-9003
limb-girdle muscular dystrophy
muscular dystrophy
gene therapy
Flag link:
Sarepta competitor files with FDA for Duchenne drug
Sarepta competitor files with FDA for Duchenne drug
Seeking Alpha
Sarepta Therapeutics
NS Pharma
golodirsen
FDA
Duchenne Muscular Dystrophy
Flag link:
Wave takes a different tack from Sarepta in Duchenne
Wave takes a different tack from Sarepta in Duchenne
EP Vantage
Wave Life Sciences
Duchenne Muscular Dystrophy
suvodirsen
Sarepta Therapeutics
Flag link:
The FDA and Sarepta: a window into the real world of drug regulation
The FDA and Sarepta: a window into the real world of drug regulation
Stat
FDA
regulatory
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
Vyondys 53
Flag link:
Sarepta now needs flawless progress for gene therapy
Sarepta now needs flawless progress for gene therapy
Biopharma Dive
Sarepta Therapeutics
FDA
Duchenne Muscular Dystrophy
Vyondys 53
gene therapy
SRP-9001
Flag link:
Sarepta Duchenne drug rejected by FDA in surprise decision
Sarepta Duchenne drug rejected by FDA in surprise decision
Biopharma Dive
Sarepta Therapeutics
Duchenne Muscular Dystrophy
FDA
complete response letter
Vyondys 53
Flag link:
Sarepta's Lone Analyst Skeptic Takes On 22 Bulls With Renewed Warnings
Sarepta's Lone Analyst Skeptic Takes On 22 Bulls With Renewed Warnings
Bloomberg
Sarepta Therapeutics
analysts
Duchenne Muscular Dystrophy
Vyondys 53
Exondys 51
Flag link:
The Week Ahead In Biotech: FDA Goes Into Overdrive In A Quiet Week
The Week Ahead In Biotech: FDA Goes Into Overdrive In A Quiet Week
Yahoo/Benzinga
Nabriva
Sarepta Therapeutics
TrovaGene
Medtronic
Flag link:
Four New Drugs are Around the Corner. Here’s What You Need to Know.
Four New Drugs are Around the Corner. Here’s What You Need to Know.
Xconomy
FDA
drug approvals
AbbVie
Upadacitinib
Exondys 51
Sarepta Therapeutics
Nabriva Therapeutics
lefamulin
Roche
Rozlytrek
Flag link:
Patient in Sarepta gene therapy trial develops serious illness; shares plunge
Patient in Sarepta gene therapy trial develops serious illness; shares plunge
Yahoo/Reuters
Sarepta Therapeutics
Duchenne Muscular Dystrophy
rhabdomyolysis
gene therapy
Flag link:
Studies Show Sarepta's Exondys 51 Slows Respiratory Decline in Muscular Dystrophy Patients
Studies Show Sarepta's Exondys 51 Slows Respiratory Decline in Muscular Dystrophy Patients
BioSpace
Sarepta Therapeutics
Exondys 51
DMD
Duchenne Muscular Dystrophy
Flag link:
UPDATED: Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER
UPDATED: Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER
Endpoints
Duchenne Muscular Dystrophy
ICER
Sarepta Therapeutics
Exondys 51
Flag link:
These 6 biotech stocks are promising takeover targets
These 6 biotech stocks are promising takeover targets
Marketwatch
M&A
Sarepta Therapeutics
Amarin
Intercept Pharmaceuticals
Immunomedics
Alder Biopharmaceuticals
Biogen
Flag link:

Pages